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Abstract 
Background: Statistical models that use an individual’s DNA methylation levels to estimate their 
age (known as epigenetic clocks) have recently been developed, with 96% correlation found 
between epigenetic and chronological age. We postulate that differences between estimated and 
actual age (age acceleration, AA), can be used as a measure of developmental age in early life.  
Methods: We obtained DNA methylation measures at three timepoints (birth, age seven and 17) 
in 1018 children from the Avon Longitudinal Study of Parents and Children (ALSPAC). Using 
an online calculator, we estimated epigenetic age, and thus AA, for each child at each timepoint. 
We then investigated whether AA was prospectively associated with repeated measures of 
height, weight, BMI, bone mineral density, bone mass, fat mass, lean mass and Tanner stage.  
Results: Positive AA at birth was associated with higher average fat mass (1321g per year of 
AA, 95% CI 386, 2256g) from birth to adolescence (i.e. from age 0-17) and AA at age 7 was 
associated with higher average height (0.23cm per year of AA, 95% CI 0.04, 0.41cm).  
Conflicting evidence for the role of AA (at birth and in childhood) on changes during 
development was also found, with higher AA being positively associated with changes in weight, 
BMI and Tanner stage but negatively with changes in height and fat mass.  
Conclusions: We found evidence that being ahead of one’s epigenetic age is related to 
developmental characteristics during childhood and adolescence. This demonstrates the potential 
for using AA as a measure of development in future research.  
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Key message 
 Children with a positive epigenetic age are taller and have higher fat mass throughout 
childhood and adolescence on average. 
 Epigenetic age acceleration is associated with longitudinal changes in weight, BMI, 
height and fat mass during childhood and adolescence. 
 We find some evidence that higher epigenetic age is positively associated with 
longitudinal Tanner stage of development in adolescents.  
 We find no association between epigenetic age and age at puberty, estimated as the 
age at peak height velocity. 
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Introduction 
Statistical models that use an individual’s DNA methylation levels to estimate their age (known 
as epigenetic clocks) have been developed(1-5). These methods have proved successful, with up 
to 96% correlation and a mean difference of three years found between estimated and actual 
age(2). A recent review(6) has also highlighted two separate processes when it comes to age 
related changes of DNA methylation levels: one reflecting overall changes in DNA methylation 
across CpG sites over the lifecourse (sometimes referred to as epigenetic drift(7-9)), which may 
be attributed to individual level environmental factors or stochastic processes. The second uses 
specific CpG sites that are affected by age in a similar fashion across individuals, and hence can 
be used to accurately predict age from DNA methylation data. Differences between 
chronological age and epigenetic age are defined as age acceleration (AA), and positive age 
acceleration (i.e. having a higher epigenetic age than chronological age) has been shown to be 
associated with obesity(10), lower physical and cognitive function(11), Alzheimer’s disease(12), 
HIV(13), menopause(14) and all-cause mortality(15-17). Since DNA methylation can be 
influenced by environmental factors(18), and in turn influence phenotypes, it is of interest to 
study both the determinants and consequences of AA. However, there is an absence of literature 
on the associations of AA with physical development in early life. The Avon Longitudinal Study 
of Parents and Children (ALSPAC)(19, 20) is a large UK birth cohort, which has followed 
roughly 14 000 children from birth, collecting many thousands of variables over time. DNA 
methylation data were obtained for 1018 of these children from umbilical cord blood (at birth) 
and venous blood at ages seven and 15 or 17 as part of the Accessible Resource for Integrated 
Epigenomic Studies (ARIES) project(21).  
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Here we use the epigenetic clock method by Horvath for the following reasons: First, it is more 
accurate than other methods when it comes to young subjects(22, 23). Second, it applies to 
virtually all tissues and cell types, which suggests that it might play a role in organismal 
development and aging. Using the Horvath age estimation method, we have calculated the 
epigenetic age for all of the children at each time point, and the resulting AA. In this paper we 
investigate the consequences of AA, by looking at standard measures of development, which 
have been repeatedly measured throughout childhood and adolescence: height, weight, body 
mass index (BMI), bone mineral density (BMD), bone mass, lean mass and fat mass.     
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Methods 
Study Population 
This study used DNA methylation data generated under the auspices of the Avon Longitudinal 
Study of Parents and Children (ALSPAC)(19, 20). ALSPAC recruited 14 541 pregnant women 
with expected delivery dates between April 1991 and December 1992. Of these initial 
pregnancies there were 14 062 live births and 13 988 children who were alive at one year of age. 
The study website contains details of all the data that are available through a fully searchable 
data dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary).  
As part of the Accessible Resource for Integrated Epigenomic Studies (ARIES)(21) project 
(http://www.ariesepigenomics.org.uk), a sub-sample of 1018 ALSPAC mother-child pairs had 
DNA methylation measured using the Infinium HumanMethylation450 BeadChip (Illumina, 
Inc.)(24). Here we use DNA methylation data generated from cord blood and venous blood 
samples at age seven and again at age 15 or 17 years, leading to three measurements of DNA 
methylation per child. All DNA methylation wet-lab and pre-processing analyses were 
performed at the University of Bristol as part of the ARIES project and has been described in 
detail previously(21, 22). 
Epigenetic age 
Using the online epigenetic clock calculator (http://labs.genetics.ucla.edu/horvath/dnamage/), we 
obtained epigenetic age for each child at each time point in ARIES. Along with epigenetic age, 
the online calculator estimates cell-type proportions and calculates raw age acceleration 
differences (estimated-chronological age) and age acceleration residuals (the residuals from a 
linear regression of epigenetic age on chronological age, which we call age acceleration and 
denote AA). These AAs are uncorrelated with chronological age and contain information about 
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the epigenetic age profiles of each sample, i.e. a positive residual corresponds to an individual 
whose epigenetic age is ahead of their chronological age and vice versa. The calculator provides 
estimates of epigenetic age, AA and AA adjusted for imputed blood cell-types. In our analysis 
we use those age acceleration residuals which have been adjusted for estimated cell type ratios. 
Developmental variables 
We obtained longitudinal data on repeatedly measured physical characteristics in ALSPAC to 
investigate the relationship between AA and development. These characteristics were height 
(cm), weight (kg), BMI (kg/m2), bone mineral density (BMD; g/cm2), bone mass (g), fat mass (g) 
and lean mass (g). Height, weight and BMI were measured from birth to age 18, with up to 19 
measurements per child, including nine after age seven; BMD, bone mass, fat mass and lean 
mass were assessed by dual energy X-ray absorptiometry (DXA) scans twice, at ages 9 and 18. 
Age at puberty was estimated by age at peak height velocity (PHV) (25) calculated using the 
SITAR model(26). We included estimated age at puberty in all longitudinal models of 
development and also investigated whether it was related to AA. Tanner(25) staging was 
repeatedly measured at mean ages 8.2, 9.7, 10.8, 11.8, 13.2 and 14.7 years. At each of these six 
ages, participants were asked to mark their development in relation to drawings of breasts 
(female), testes (male) and pubic hair (both male and female) development which were on a 
graphical scale from 1 (no development) to 5 (adult development).   
Statistical analysis 
A single multilevel model was used to investigate the association between chronological and 
epigenetic ages. Using the multilevel model, we can include the measures of epigenetic age (as a 
repeated outcome) and calculate an intra-class correlation coefficient (ICC), a number between 0 
and 1 which suggests the proportion of variation (here in epigenetic age) which is explained by 
 Page 8 of 28 
 
between individual differences. The association between AA and developmental timing was 
assessed using Pearson correlation between AA (at birth, age 7 and age 17) and SITAR estimated 
age at peak height velocity (PHV). Multilevel models of the four ordinal Tanner stage variables, 
corrected for age at Tanner measurement were used to assess the association of AA at birth and 
age 7 on developmental timing. We also combined the pubic hair Tanner stage variables for boys 
and girls, and the breast/testes Tanner stage variables across boys and girls, in order to increase 
the power to detect an association with AA. Each model was adjusted for longitudinal cell 
composition estimated using the Houseman method(27).    
Body composition data were modelled using multilevel models(28, 29), with AA (at birth and 
seven) included as a fixed effect along with an interaction of AA (at birth and age seven) with 
age to determine the effect of AA on changes in developmental characteristics. AA at age 17 was 
not considered as an exposure, since it was recorded at the end the follow-up period, with few 
measures of the key traits occurring after it. In each multilevel model we included sex, birth 
weight, gestational age, parity, delivery method, maternal age, maternal smoking, maternal 
alcohol consumption and maternal education level attained to adjust for potential confounding. 
Longitudinal cell counts (estimated using the Houseman method(27)) were also included, to 
adjust for the effect of changes in blood cell composition over the lifecourse. To correct for 
temporality issues, only measures of development taken after AA were included in the multilevel 
models, e.g. AA at age seven could only affect height measures after age seven. Weight was log-
transformed to correct for non-constant variance over age (variance of weight increases over the 
lifecourse). Cubic spline terms were used to account for the nonlinear changes in height, log-
weight and BMI. The placement of knots was based on previous research(30-32). For example 
the multilevel model for height was: 
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heightij = β0i + β1iageij + β2AA0 + β3AA7 + β4 AA0*ageij + β5 AA7*ageij + fi(ageij) + β6sex + 
β7parity + β8birthweight + β9gestationalage + β10caesarean + β11maternalage + 
β12maternalsmoking + β13maternalalcohol + β14maternaleducaiton + β15CD8tCellsProp + 
β16CD4tCellsProp + β17NaturalKillerCellsProp + β18BcellsProp + β19MonocytesProp + 
β20GranulocytesProp 
 
where ℎ𝑒𝑖𝑔ℎ𝑡𝑖𝑗 is the 𝑗th height measurement from the 𝑖th individual for 𝑖 = 1,… , 𝑛 individuals 
and 𝑗 = 1,… , 𝑛𝑖 measures. 𝛽0𝑖 and 𝛽1𝑖 represent the 𝑖th individual’s random intercept and slope; 
𝑓𝑖 is a cubic spline which explains the height trajectory of individual 𝑖; 𝛽2 and 𝛽3 explain the 
association of age acceleration (at birth [𝐴𝐴0] and 7 [𝐴𝐴7] respectively) and average 
development; 𝛽4 and 𝛽5 explain the association of AA (at birth [𝐴𝐴0] and 7 [𝐴𝐴7] respectively) 
on changes in development; 𝛽6 to 𝛽14 describe associations between development and 
confounder variables; and 𝛽15 to 𝛽20 control for estimated cell composition(27). 
Sensitivity analyses 
We carry out two sensitivity analyses, modelling longitudinal physical development as above (A) 
with adjustment for age at puberty estimated using SITAR(26) and (B) without adjusting for cell 
type composition estimated using the Houseman method(27). 
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Results 
A summary of the cohort under investigation is given in Table 1. Epigenetic age at birth was 
0.26 years on average; chronological age was lower than epigenetic age at the childhood 
timepoint (mean chronological 7.49, epigenetic 8.25) but similar at the adolescent timepoint 
(mean chronological 17.14, epigenetic 17.20). We find low Pearson correlation coefficients 
between chronological age and estimated age (r=0.058 and 0.245 at childhood and adolescence, 
respectively); this reflects the low standard deviations in chronological age (SD=0.15 in 
childhood SD= 1.01 years in adolescence). High correlations (such as the r=0.96 observed in the 
studies used to develop the measure of epigenetic age) were observed in data sets comprised of a 
wide range of chronological ages(2). Correlations between estimated age and actual age are 
similar to the original Horvath paper when including data from across multiple time points; 
taking one random measure from each person, the correlation between epigenetic and actual age 
was 0.85 (Figure 1). Using a multilevel model including all measures of epigenetic and actual 
age, the coefficient of age was 0.985 (95% CI 0.97, 1.00). This suggests that for each year of life, 
epigenetic age increases by 0.985 years on average. From this model, the intra-class correlation 
coefficient for epigenetic age was 0.12, which suggests that 12% of the variation in epigenetic 
age is between individuals. 
AA at birth 
AA was not associated with average length at birth (0.16cm per year of AA, 95% CI -0.08, 
0.39cm; p=0.19) or height growth (0.017cm/year per year of AA, 95% CI -0.067, 0.10cm/yr; 
p=0.69). There was evidence that children with higher AA at birth had faster growth in weight 
(0.25%/year faster growth per year of AA, 95% CI 0.034, 0.459%/year; p=0.023) and BMI 
(0.035kg/m2/year faster growth per year of AA, 95% CI -0.0037, 0.066kg/m2/year; p=0.030) 
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during childhood and adolescence. There was little evidence for an association between AA at 
birth and either average bone mineral density (0.003g/cm3 per year of AA, 95% CI -0.006, 
0.012g/cm3; p=0.478) or bone mass (19.71g per year of AA, 95% CI -30.8, 70.2g; p=0.45). A 1-
year higher AA at birth was associated with 1321g higher fat mass on average across childhood 
(95% CI 386, 2256g; p=0.006), but this difference narrowed over time, with higher AA children 
having a slower growth of fat mass during childhood and adolescence (112.5g/year slower 
growth, 95% CI 31, 194g/year slower; p=0.007). AA at birth was not associated with average 
lean mass (-74.5g per year of AA, 95% CI -1502, 1353g; p=0.918). 
AA in childhood 
Higher AA at age seven was associated with increased height (Table 2). Children with a 1-year 
higher AA at seven were 0.23cm taller on average (95% CI 0.04, 0.41cm; p=0.018) between 
seven and 17 years of age. AA at age seven was also associated with changes in height, with a 1-
year positive AA being associated with slower growth of height (-0.031cm/year, 95% CI -0.005, 
-0.057cm/year; p=0.021) from seven to 17 years. There was no evidence of an association 
between AA at age seven and either average weight (-0.11% per year of AA, 95% CI -0.69, 
0.48%; p=0.72) or BMI (-0.04kg/m2 per year of AA, 95% CI -0.11, 0.03kg/m2; p=0.28). We did 
not identify any associations between AA at age seven and either average BMD (-0.001g/cm3 per 
year of AA, 95% CI -0.0036, 0.0015g/cm3; p=0.418), bone mass (-7.16g per year of AA, 95% CI 
-21.8g, 7.5g; p=0.34), fat mass (67.2g per year of AA, 95% CI -205, 339g; p=0.63) and lean 
mass (-206g per year of AA, 95% CI -605, 192g; p=0.24) 
Role of age at puberty 
AA at birth (Pearson r=0.006, p=0.85), seven (r=0.014, p=0.67) and 17 (r=0.014, p=0.66) were 
not associated with age at PHV estimated by the SITAR model.  The odds ratios from multilevel 
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models of ordinal Tanner stages of development are presented in Table 3. Those boys with a 
positive epigenetic age at birth had higher odds of increasing Tanner stage of testes development 
(OR 1.10, 95% CI 1.01, 1.20; p=0.03). Further, combining across both sexes, there was some 
evidence that those children with positive epigenetic age at birth had higher odds of increasing 
pubic hair development in adolescence (OR 1.05, 95% CI 1.00, 1.11; p=0.06). There was no 
evidence that AA at age 7 was associated with any longitudinal Tanner measure of development. 
Sensitivity analysis 
In Table 4 we provide the results of models that are adjusted for age at puberty, for comparison 
with Table 2. While there is a general pattern of attenuation of the associations of AA with 
physical development after adjustment for age at puberty, there are no changes to the overall 
patterns of association described in the previous sections.  
Table 5 displays results unadjusted for longitudinal cell composition, as estimated by the 
Houseman method(27). Here AA at age 7 appears to be associated with changes in both bone 
mass and lean mass. Associations between AA at 7 and height are similar with and without 
adjustment, as are all associations of AA at birth.  
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Discussion 
Positive epigenetic age acceleration in early life appears to be associated with several 
developmental variables and changes in these variables during childhood. We have identified 
positive associations between AA and average height, average fat mass, and increased weight 
and BMI gain. Conversely, there were negative associations between AA and changes in height 
and fat mass. A systematic difference between epigenetic and actual age at the ARIES childhood 
timepoint was found (mean actual 7.49 years, mean epigenetic 8.25 years). There may be 
population differences between the ARIES population and the cohorts of children used to 
develop the Horvath age estimation method. For example, the Alisch et al dataset(33) has a 
higher proportion with non-European ancestry (>15%) and uses the Illumina 27k rather than 
450k array to estimate epigenetic age. The systematic difference at childhood could further be 
influenced by the spread of the estimated epigenetic ages for the childhood timepoint (standard 
deviation 2.4 years, range 2.5-25 years) when compared to the spread of actual age at childhood 
(standard deviation 0.15 years, range 7.1-9.1 years). 
The findings reported here are independent of sex (sex differences in AA  have been previously 
reported(22)), with all analyses controlled for sex. Those children with higher AA at age seven 
are taller on average with lower lean and bone mass. This suggests that there may be an 
identifiable developmental type, with higher AA in early life. Studies of AA in adults have 
identified a positive association between AA and obesity(10) and all-cause mortality(15). Given 
that BMI and general adiposity are associated with an increased risk of mortality(34, 35), this 
suggests an epigenetic age lower than one’s actual age (i.e. negative AA) is desirable. We have 
found some evidence to suggest that growth of BMI is faster in children whose DNA 
methylation levels at birth lead to a positive AA. This is congruent with several previous 
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findings(10, 22), and suggests the link between AA and BMI manifests from birth. However, it is 
not yet clear whether positive AA is harmful during childhood. Indeed, it could be taken from 
our results that a positive AA suggests above average development (which is not always a health 
positive, e.g. BMI). For example, we have also identified positive associations between AA and 
height and fat mass.  
While our study found at best a suggestive relationship between AA at birth and the role of sex 
hormones (Tanner stage), another study in adults found that the loss of sex hormones (resulting 
from menopause) was associated with increased epigenetic age acceleration in blood(14). 
However, we did not identify any association between AA and age at puberty (estimated by age 
at peak height velocity). One might expect that age at puberty (an obvious marker of 
developmental age) would be associated with epigenetic age but its inclusion in the modelling of 
development failed to influence the effect of AA. Further, a recent study of children who suffer 
from a severe developmental disorder found no evidence for a difference in epigenetic and 
chronological age(23). These null findings temper our conclusions on the relationship between 
AA and physical development. On the other hand, measurement error and tissue specificity may 
play a role. We used age at peak height velocity (i.e. the age at which adolescents grow fastest) 
estimated by the SITAR model(26) as a marker for age at puberty. Obtaining an accurate 
measure of age at puberty is difficult, and our null finding may be to do with poor estimates of 
age at puberty. Another possibility is that blood cells are not the optimal tissue for relating 
epigenetic age and physical development.   
Future longitudinal studies of AA may be able to provide evidence as to the changing role of 
epigenetic age across the lifecourse. Causal inference methods, such as Mendelian 
randomisation(36), should be implemented to investigate the influence of epigenetic age and 
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AA(37) on development, perhaps using genetic variants close to the 353 CpG sites (these are 
described in our Supplementary material) which are used to estimate epigenetic age. Since 
Mendelian randomisation will require a large sample size to be adequately powered, 
collaboration between cohort studies with epigenetic and longitudinal data will be key to this 
endeavour.  
A novel application of the epigenetic clock in physical development should involve the 
comparison of epigenetic age (and AA) between tissue types on the same individuals. 
Comparisons of epigenetic age of bone, blood and adipose tissue for example, could lead to 
novel insights into well-known associates of development and how they interact with changes 
across the lifecourse. Another potential avenue is to use AA as an aggregate measure of 
development. While our analysis has identified several associations, larger studies could identify 
stronger (and possibly causal) links between AA and development. Using AA as a marker for 
development would simplify analyses where difficulty lies in choosing which aspects of 
development to adjust for. 
We have not been able to replicate our longitudinal analysis findings in an independent cohort 
due to the unique nature of our data set. Since measured cell type proportions were not available 
in ARIES, we have adjusted for estimated cell type proportions from the online 
calculator (http://labs.genetics.ucla.edu/horvath/dnamage/), which uses the Houseman 
method(27). This raises the possibility that differences observed can be explained by longitudinal 
(possibly developmental) changes in white blood cell profiles not captured by these estimates. 
While adjusting for cell type is good practice, care should be taken when adjusting for cell 
composition in early life, since the Houseman method has not been validated in cord blood 
samples or in very young children and it may lead to biased results. In this manuscript we have 
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shown the results both adjusted and unadjusted for Houseman estimated cell counts. We 
observed that the association between epigenetic age and both bone and lean mass appears to be 
explained by changing cell type composition across childhood and adolescence. However, this 
may be due to a bias introduced using the Houseman method on cord blood samples. Recently, 
reference datasets for cell type correction in cord blood have been released(38, 39). 
Unfortunately using these in longitudinal modelling through childhood and adolescence is 
difficult since these methods do not estimate the same cell types as those in venous blood drawn 
from the peripheral circulation. 
Our main findings were obtained across seven multilevel models, each with two parameters of 
interest and should thus be interpreted in light of this multiple testing burden. The association of 
AA with changes in height could be explained by regression to the mean. For instance, we find 
positive AA is associated with being taller on average at age seven, but also that positive AA is 
associated with slower growth from seven to 17 such that, on average, children will end up with 
similar heights at age 17 regardless of AA. 
Epigenetic age acceleration in early life is associated with several developmental characteristics 
throughout childhood and adolescence, but with associations not all in the same direction, and no 
observed association with age at puberty. The consideration of epigenetic age as an index of 
developmental stage is a novel concept that adds to the growing literature around age 
acceleration and its use as a measure of development aging. Further longitudinal and causal 
analyses are needed to investigate the influences and consequences of age acceleration.  
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Table 1: Characteristics of the ARIES sample 
Variable Timepoint Mean SD Min Max N (%) 
Age (Years) 7yr  7.49 0.15 7.10 9.08  
 17yr  17.14 1.01 14.69 19.33  
DNA methylation age (Years) Birth 0.26 0.63 -0.59 16.68  
 7yr   8.25 2.42 2.50 24.80  
 17yr   17.20 4.34 3.77 31.65  
Height (cm) 7yr 126.24 5.29 109.20 141.60  
 17yr 171.93 9.11 152.20 197.50  
Weight (kg) 7yr   26.22 4.73 17.60 51.40  
 17yr 66.99 14.92 44.20 147.40  
BMI (kg/m2) 7yr   16.37 2.22 12.65 29.15  
 17yr 22.61 4.47 16.26 50.06  
BMD (g/cm2) 17yr  1.19 0.10 0.95 1.56  
Bone mass (g) 17yr 2814 547 1683 4666  
Fat mass (g) 17yr 18005 11478 3485 82194  
Lean mass (g) 17yr  46623 10106 27535 76425  
Birth weight (g)  3418 547 645.00 5640  
Gestational age at delivery (Weeks)  39.46 1.86 25.00 47.00  
Parity (# previous pregnancy)  0.7 0.8 0 5  
Maternal age at pregnancy (Years)  29.2 4.4 17 42  
Sex Male     445 (49) 
 Female     469 (51) 
Delivery method Caesarean     83 (9) 
 Natural     795 (91) 
Maternal smoking in pregnancy Never     545 (61) 
 Quit     248 (28) 
 Smoker     101 (11) 
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Table 2: Age acceleration and physical development1  
Outcome2 Exposure Mean 
difference in 
outcome per 
1-year 
greater AA 
95% CI p-value Mean 
difference in 
change in 
outcome per 
year per 1-
year greater 
AA 
95% CI p-value 
Height (cm) AA at 0 0.16 -0.08,0.39 0.184 0.012 -0.071,0.094 0.783 
 AA at 7 0.23 0.04,0.41 0.018 -0.031 -0.057,-0.005 0.021 
Weight (%)3 AA at 0 -1.16 -2.86,0.57 0.189 0.246 0.034,0.459 0.023 
 AA at 7 -0.11 -0.69,0.48 0.719 -0.001 -0.072,0.071 0.981 
BMI (kg/m2) AA at 0 -0.07 -0.18,0.04 0.227 0.035 0.003,0.066 0.030 
 AA at 7 -0.04 -0.11,0.03 0.282 0.004 -0.01,0.01 0.423 
BMD (g/cm2) AA at 0 0.0032 -0.0056,0.0119 0.478 -0.0002 -0.0010,0.0006 0.600 
 AA at 7 -0.0010 -0.0036,0.0015 0.418 0.0001 -0.0001,0.0003 0.298 
Bone mass (g) AA at 0 19.71 -30.83,70.24 0.445 -0.66 -4.98,3.66 0.765 
 AA at 7 -7.16 -21.84,7.51 0.339 1.07 -0.16,2.31 0.089 
Fat mass (g) AA at 0 1320.8 385.85,2255.7 0.006 -112.58 -194.39,-30.77 0.007 
 AA at 7 67.26 -204.73,339.24 0.628 -3.92 -27.30,19.46 0.742 
Lean mass (g) AA at 0 -74.51 -1501.6,1352.5 0.918 20.72 -80.98,122.43 0.690 
 AA at 7 -206.22 -605.36,192.92 0.311 20.45 -7.77,48.67 0.155 
   
                                                 
1 all models adjusted for estimated cell counts, sex, birth weight, gestational age, parity, delivery method, maternal 
age, maternal smoking, maternal alcohol consumption and maternal education level attained 
2 all outcome measurements come either concurrently or after the age at which AA is estimated 
3 weight was log-transformed such that back-transformed coefficients represent % change in weight 
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Table 3: Results from multilevel ordinal models of Tanner stage variables against age acceleration 
at birth and age 7, controlling for age at measurement of Tanner stage 
Outcome Exposure Odds ratio (per year of AA) 95% CI p-value n 
Tanner girls genitals AA at 0 1.11 0.87,1.42 0.39 459 
 AA at 7 0.99 0.73,1.34 0.94 458 
Tanner girls pubic hair AA at 0 1.11 0.65,1.88 0.70 410 
 AA at 7 1.11 0.60,2.07 0.74 415 
Tanner boys genitals AA at 0 1.10 1.01,1.20 0.03 477 
 AA at 7 1.04 0.94,1.15 0.44 475 
Tanner boys pubic hair AA at 0 1.00 0.92,1.07 0.90 448 
 AA at 7 0.96 0.88,1.05 0.37 453 
Tanner genitals AA at 0 1.00 0.92,1.07 0.90 448 
 AA at 7 0.96 0.88,1.05 0.37 453 
Tanner pubic hair AA at 0 1.05 1.00,1.11 0.06 925 
 AA at 7 0.99 0.93,1.06 0.79 928 
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Table 4: Age acceleration and physical development with adjustment for age at puberty4  
Outcome5 Exposure Mean 
difference in  
outcome per 
1-year 
greater AA 
95% CI p-value Difference in 
average 
change in 
outcome per 
1-year 
positive AA 
95% CI p-value 
Height (cm) AA at 0 0.17 -0.07,0.40 0.167 0.009 -0.074,0.092 0.828 
 AA at 7 0.22 0.04,0.41 0.019 -0.031 -0.058,-0.005 0.022 
Weight (%)6 AA at 0 -0.95 -2.60,0.72 0.262 0.198 0.001,0.396 0.049 
 AA at 7 -0.13 -0.69,0.44 0.653 0.002 -0.064,0.069 0.949 
BMI (kg/m2) AA at 0 -0.06 -0.18,0.05 0.271 0.032 0.001,0.063 0.042 
 AA at 7 -0.04 -0.11,0.03 0.245 0.005 -0.01,0.01 0.356 
BMD (g/cm2) AA at 0 0.0026 -0.0063,0.0115 0.565 -0.0002 -0.0010,0.0006 0.617 
 AA at 7 -0.0012 -0.0037,0.0014 0.379 0.0001 -0.0001,0.0003 0.268 
Bone mass (g) AA at 0 17.21 -34.08,68.50 0.511 -0.68 -4.99,3.63 0.756 
 AA at 7 -7.93 -22.80,6.93 0.295 1.03 -0.20,2.27 0.101 
Fat mass (g) AA at 0 1253.7 325.44,2182.0 0.008 -111.41 -191.95,-30.88 0.007 
 AA at 7 40.43 -229.68,310.54 0.769 -3.79 -26.88,19.30 0.748 
Lean mass (g) AA at 0 -93.80 -1513.8,1326.2 0.897 19.67 -81.48,120.83 0.703 
 AA at 7 -239.08 -636.16,157.99 0.238 21.93 -6.13,49.98 0.126 
 
  
                                                 
4 all models adjusted for age at puberty, estimated cell counts, sex, birth weight, gestational age, parity, delivery 
method, maternal age, maternal smoking, maternal alcohol consumption and maternal education level attained 
5 all outcome measurements come either concurrently or after the age at which AA is estimated 
6 weight was log-transformed such that back-transformed coefficients represent % change in weight 
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Table 5: Age acceleration and physical development without adjusting for cell type proportions7  
Outcome8 Exposure Mean 
difference in 
outcome per 
1-year 
greater AA 
95% CI p-value Mean 
difference in 
change in 
outcome per 
year per 1-
year greater 
AA 
95% CI p-value 
Height (cm) AA at 0 0.17 -0.06,0.40 0.142 0.011 -0.072,0.093 0.802 
 AA at 7 0.21 0.03,0.40 0.025 -0.033 -0.059,-0.007 0.014 
Weight (%)9 AA at 0 -0.99 -2.68,0.74 0.260 0.233 0.018,0.448 0.034 
 AA at 7 -0.09 -0.67,0.49 0.751 -0.002 -0.074,0.071 0.966 
BMI (kg/m2) AA at 0 -0.08 -0.19,0.03 0.151 0.035 0.004,0.066 0.028 
 AA at 7 -0.04 -0.10,0.03 0.304 0.004 -0.01,0.01 0.413 
BMD (g/cm2) AA at 0 0.0026 -0.0061,0.0114 0.556 -0.0002 -0.0010,0.0006 0.596 
 AA at 7 -0.0015 -0.0040,0.0010 0.235 0.0001 -0.0001,0.0004 0.218 
Bone mass (g) AA at 0 14.79 -36.80,66.38 0.574 -0.58 -4.97,3.80 0.794 
 AA at 7 -11.99 -26.50,2.52 0.105 1.29 0.05,2.54 0.042 
Fat mass (g) AA at 0 1289.8 355.91,2223.7 0.007 -108.21 -190.09,-26.34 0.010 
 AA at 7 81.73 -181.36,344.83 0.543 -5.03 -28.25,18.18 0.671 
Lean mass (g) AA at 0 -140.32 -1605.1,1324.4 0.851 21.15 -82.88,125.18 0.690 
 AA at 7 -306.20 -708.80,96.41 0.136 25.33 -3.32,53.97 0.083 
  
                                                 
7 all models adjusted for sex, birth weight, gestational age, parity, delivery method, maternal age, maternal smoking, 
maternal alcohol consumption and maternal education level attained 
8 all outcome measurements come either concurrently or after the age at which AA is estimated 
9 weight was log-transformed such that back-transformed coefficients represent % change in weight 
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Figure 1: Epigenetic age against actual age for a random sample of 1000 ARIES offspring taken 
from across the three timepoints. 
 
